Approximately 30–40% of mCRPC patients may show no response to 177Lu-PSMA therapy for various reasons, including tumor biology, disease extent, and prior treatments that may contribute to heterogeneous or low PSMA expression through an aggressive trans-differentiation process [38,39]. Here, FOLH1 is linked to neoplasm.